4.6 Article

The C Proteins of Human Parainfluenza Virus Type 1 Block IFN Signaling by Binding and Retaining Stat1 in Perinuclear Aggregates at the Late Endosome

期刊

PLOS ONE
卷 7, 期 2, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0028382

关键词

-

资金

  1. National Institute of Allergy and Infectious Diseases, National Institutes of Health
  2. NIH
  3. MedImmune, LLC

向作者/读者索取更多资源

Interferons (IFNs) play a crucial role in the antiviral immune response. Whereas the C proteins of wild-type human parainfluenza virus type 1 (WT HPIV1) inhibit both IFN-beta induction and signaling, a HPIV1 mutant encoding a single amino acid substitution (F170S) in the C proteins is unable to block either host response. Here, signaling downstream of the type 1 IFN receptor was examined in Vero cells to define at what stage WT HPIV1 can block, and F170S HPIV1 fails to block, IFN signaling. WT HPIV1 inhibited phosphorylation of both Stat1 and Stat2, and this inhibition was only slightly reduced for F170S HPIV1. Degradation of Stat1 or Stat2 was not observed. The HPIV1 C proteins were found to accumulate in the perinuclear space, often forming large granules, and co-localized with Stat1 and the cation-independent mannose 6-phosphate receptor (M6PR) that is a marker for late endosomes. Upon stimulation with IFN-beta, both the WT and F170S C proteins remained in the perinuclear space, but only the WT C proteins prevented Stat1 translocation to the nucleus. In addition, WT HPIV1 C proteins, but not F170S C proteins, co-immunoprecipitated both phosphorylated and unphosphorylated Stat1. Our findings suggest that the WT HPIV1 C proteins form a stable complex with Stat1 in perinuclear granules that co-localize with M6PR, and that this direct interaction between the WT HPIV1 C proteins and Stat1 is the basis for the ability of HPIV1 to inhibit IFN signaling. The F170S mutation in HPIV1 C did not prevent perinuclear co-localization with Stat1, but apparently weakened this interaction such that, upon IFN stimulation, Stat1 was translocated to the nucleus to induce an antiviral response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)

Harrison C. Bergeron, Ralph A. Tripp

Summary: Nirsevimab (MEDI8897) is a monoclonal antibody targeting the RSV F protein with an extended half-life, developed for the prevention of LRTI caused by RSV. It is a next-generation RSV medicine that only requires a single dose to protect infants for the entire RSV season. Despite the approval of nirsevimab, there is still a need for more effective RSV vaccines and treatments.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

Article Medicine, Research & Experimental

T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity

Rebecca Elyanow, Thomas M. Snyder, Sudeb C. Dalai, Rachel M. Gittelman, Jim Boonyaratanakornkit, Anna Wald, Stacy Selke, Mark H. Wener, Chihiro Morishima, Alexander L. Greninger, Michael Gale, Tien-Ying Hsiang, Lichen Jing, Michael R. Holbrook, Ian M. Kaplan, H. Jabran Zahid, Damon H. May, Jonathan M. Carlson, Lance Baldo, Thomas Manley, Harlan S. Robins, David M. Koelle

Summary: This study suggests that measuring T cell responses can provide reliable assessment of past SARS-CoV-2 infection and protective immunity. T cell responses showed significant correlations with neutralizing antibody titers and disease severity indicators. T cell testing demonstrated high sensitivity even after 6 months of infection, outperforming serology tests in identifying prior infection, especially in individuals with milder disease.

JCI INSIGHT (2022)

Article Biology

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit

Nicholas K. Hurlburt, Leah J. Homad, Irika Sinha, Madeleine F. Jennewein, Anna J. MacCamy, Yu-Hsin Wan, Jim Boonyaratanakornkit, Anton M. Sholukh, Panpan Zhou, Dennis R. Burton, Raiees Andrabi, Leonidas Stamatatos, Marie Pancera, Andrew T. McGuire, Gabriel Ozorowski, Andrew B. Ward

Summary: Structural and functional characterisation of antibody CV3-25 reveals its wide neutralisation spectrum against multiple SARS-CoV2 variants, including the Alpha, Delta, Gamma, and Omicron variants, as well as a SARS-CoV-like bat coronavirus. This study highlights the importance of CV3-25 as a potential therapeutic and vaccine candidate for broad protection against coronaviruses.

COMMUNICATIONS BIOLOGY (2022)

Review Infectious Diseases

Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections

Jim Boonyaratanakornkit, Michael Boeckh, Alpana Waghmare

Summary: Monoclonal antibody administration is an important strategy for preventing and treating respiratory viral infections in vulnerable populations. Recent innovations have led to the development of novel mAbs against viruses like SARS-CoV-2, although the emergence of variants poses challenges. Clinical efficacy of mAbs can be improved by modulating factors such as Fc modifications to increase bioavailability and half-life. The landscape of mAbs for respiratory viruses is evolving rapidly with both successes and failures, but the armamentarium of available mAbs is expected to continue growing.

CURRENT OPINION IN INFECTIOUS DISEASES (2022)

Letter Hematology

Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor-modified T-cell therapy

Michael A. Gonzalez, Atif M. Bhatti, Kristin Fitzpatrick, Jim Boonyaratanakornkit, Meei-Li Huang, Victoria L. Campbell, Jessica Hecht, Sarah Ibrahimi, Shera N. Wanner, Damian J. Green, David G. Maloney, Jordan Gauthier, Andrew J. Cowan, Alexander L. Greninger, Elizabeth M. Krantz, David M. Koelle, Joshua A. Hill

BLOOD ADVANCES (2023)

Article Surgery

Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy

Joshua A. Hill, Erika S. Kiem, Atif Bhatti, Winnie Liu, Jacob Keane-Candib, Kristin S. Fitzpatrick, Jim Boonyaratanakornkit, Rebecca A. Gardner, Damian J. Green, David G. Maloney, Cameron J. Turtle, Jodi M. Smith, Idoia Gimferrer, Christopher D. Blosser, Shaun W. Jackson

Summary: The presence of anti-HLA antibodies hinders successful organ transplantation. B cell-depleting treatments have limited effectiveness in reducing these antibodies. This study suggests that long-lived plasma cells, not effectively targeted by B cell depletion, are the primary source of anti-HLA antibodies. Plasma cell-targeted therapies may be more effective in managing HLA antibodies and improving access to organ transplantation.

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

Article Immunology

Validation of Ligand Tetramers for the Detection of Antigen-Specific Lymphocytes

Kristin S. Fitzpatrick, Hanna N. Degefu, Katrina Poljakov, Madeleine G. Bibby, Allison J. Remington, Tyler G. Searles, Matthew D. Gray, Jim Boonyaratanakornkit, Pamela C. Rosato, Justin J. Taylor

Summary: The study of Ag-specific lymphocytes has made significant advancements in immunology. However, there is a lack of quality control and evaluation for the probes used in these studies. To address this issue, researchers have developed a bead-based multiplexed approach to assess the performance and stability of peptide:MHC and antigen tetramers. This study has revealed batch-to-batch variability and highlighted the potential for standardized assays to reduce technical variation and experimental failures caused by underperforming probes.

JOURNAL OF IMMUNOLOGY (2023)

Article Virology

Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein

Harrison C. Bergeron, Jackelyn Murray, Aakash Arora, Ana M. Nunez M. Castrejon, Rebecca M. DuBois, Larry J. Anderson, Lawrence M. Kauvar, Ralph A. Tripp

Summary: Respiratory syncytial virus (RSV) causes respiratory disease in infants and elderly. Current immune prophylaxis is limited to anti-RSV fusion (F) protein monoclonal antibody (mAb). However, mAbs targeting the attachment (G) protein are necessary to prevent aberrant pathogenic responses. Two high-affinity anti-G protein mAbs, 3D3 and 2D10, have been identified as effective in neutralizing RSV and reducing disease. This study compares the neutralization and immune responses of 3D3, 2D10, and palivizumab in a mouse model of RSV infection.

VIRUSES-BASEL (2023)

Article Multidisciplinary Sciences

Cross-protective antibodies against common endemic respiratory viruses

Madelyn Caban, Justas V. V. Rodarte, Madeleine Bibby, Matthew D. D. Gray, Justin J. J. Taylor, Marie Pancera, Jim Boonyaratanakornkit

Summary: This study identified two cross-neutralizing monoclonal antibodies that target both HPIV3 and HPIV1, and RSV and HMPV respectively. The in vitro and in vivo experiments demonstrated their efficacy and provided structural basis for their binding and neutralization. Therefore, a combination of these two antibodies could provide broad protection against four respiratory viruses that cause significant morbidity and mortality in at-risk individuals.

NATURE COMMUNICATIONS (2023)

Review Immunology

Understanding immunity to influenza: implications for future vaccine development

Ralph A. Tripp

Summary: Influenza virus constantly changes, making it difficult to develop immunity through vaccination. Efforts are being made to develop universal vaccines that can protect against various strains of influenza viruses. Understanding the host immune response is crucial for vaccine development.

EXPERT REVIEW OF VACCINES (2023)

Article Virology

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19

David E. Martin, Neelam Pandey, Purvi Chavda, Gurpreet Singh, Rakesh Sutariya, Frederic Sancilio, Ralph A. Tripp

Summary: This study suggests that treating symptomatic mild-to-moderate COVID-19 patients with probenecid can significantly decrease the time to viral clearance and result in a higher proportion of complete symptom resolution by day 10.

VIRUSES-BASEL (2023)

Review Microbiology

Interferons-Implications in the Immune Response to Respiratory Viruses

Harrison C. Bergeron, Matthew R. Hansen, Ralph A. Tripp

Summary: This review examines the roles and functions of type I, II, and III IFN responses to respiratory virus infections, as well as the specific IFN responses underlying immunity and protection from disease.

MICROORGANISMS (2023)

Article Infectious Diseases

Anti-G protein antibodies targeting the RSV G protein CX3C chemokine region improve the interferon response

Harrison C. Bergeron, Lawrence M. Kauvar, Ralph A. Tripp

Summary: This study investigates how monoclonal antibodies against the RSV F and G proteins modify the type I and III IFN responses to RSV infection. The findings reveal that an anti-G protein monoclonal antibody improves the protective early antiviral response, which has important implications for vaccine and therapeutic design. This research provides insights into the role of G protein antibodies in improving IFN responses against RSV disease.

THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE (2023)

Article Virology

Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19

Ralph A. Tripp, David E. Martin

Summary: In the early stages of drug discovery, assays are developed to evaluate the effectiveness of new and known molecular entities, primarily targeting specific features within the virus. However, screening efforts often prioritize finding active antiviral drugs against known viral targets, overlooking drugs that inhibit virus replication by targeting host genes or pathways.

VIRUSES-BASEL (2023)

Proceedings Paper Engineering, Mechanical

Rapid and high-sensitive LSPR sensor for coronavirus detection

Yanjun Yang, Jackelyn Murray, James Haverstick, Ralph A. Tripp, Yiping Zhao

Summary: This paper presents a rapid coronavirus detection method using a LSPR sensor based on functionalized silver nanotriangle array and ACE2 protein, which shows high sensitivity and specificity with a short detection time.

CHEMICAL, BIOLOGICAL, RADIOLOGICAL, NUCLEAR, AND EXPLOSIVES (CBRNE) SENSING XXIII (2022)

暂无数据